Vycor Medical Announces Q2 2026 Results: VBAS Revenue Dips, NovaVision Grows

Vycor Medical, Inc. (OTCQB: VYCO), a Boca Raton-based medical technology company, has announced its financial results for the second quarter and first half of 2026. The company operates through two business units: Vycor Medical, which produces the ViewSite™ Brain Access System (VBAS) for neurosurgeons, and NovaVision, which offers vision rehabilitation therapies for patients recovering from visual disorders after stroke or brain injury. In the second quarter, total revenue decreased 16% to $418,264, primarily due to a 17% decline in international sales for the VBAS division. However, NovaVision's revenue grew 17% to $17,040. On a GAAP basis, the company reported an operating profit of $6,851 for the quarter, down from $51,146 in the prior year, while non-GAAP operating profit was $22,952, down from $85,712. For the six-month period, revenue decreased 6% to $876,804, with operating profit of $52,659 (GAAP) and $82,740 (non-GAAP). The company also highlighted three new peer-reviewed studies published on VBAS, bringing the total to 53 peer-reviewed papers and 14 other clinical papers. These studies demonstrate the safety and efficacy of VBAS, including fewer neurological deficits compared to traditional retractors and effective decompression of posterior fossa metastases. The company remains focused on expanding its product portfolio and advancing its NovaVision therapies, which are still in development. For more information, visit www.vycormedical.com.

The financial results reflect the company's ongoing efforts to navigate market challenges while investing in clinical evidence and product development. The decrease in international sales is attributed to the lumpy nature of such orders, with large orders sometimes falling in different quarters. Despite the revenue decline, the company maintained a strong gross margin of 82% for the quarter. Operating expenses decreased slightly on a non-GAAP basis, reflecting disciplined cost management. The company's cash position and balance sheet were not detailed in the release, but the company continues to operate with a focus on long-term growth. The new clinical studies are expected to strengthen the value proposition of VBAS and potentially drive adoption in the neurosurgical community.

Vycor Medical is dedicated to providing innovative and superior surgical and therapeutic solutions, with a portfolio of FDA-cleared products. The VBAS system is used in over 350 hospitals in the US and internationally, protected by 49 issued and 8 pending patents. NovaVision's Visual Restoration Therapy (VRT) is the only FDA-cleared therapy for vision rehabilitation following neurological brain damage, and its NeuroEyeCoach program has shown improvements in over 80% of patients in a large study. The company continues to invest in these therapies to unlock their market potential. The full financial statements and non-GAAP reconciliations are available in the release. Vycor Medical's common stock trades on the OTCQB under the symbol VYCO.